Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153251 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Relapsed and/or Refractory Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 187
- Enrollment target
- 19
- Study locations
NCT06153251 is a Phase 1 study of Relapsed and/or Refractory Multiple Myeloma that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 187 participants. The trial reports 19 study locations across 11 states.
The verdict
NCT06153251, a Phase 1 study of Relapsed and/or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 187 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG BMS-986453
Study Locations (19)
Other
- Hôpital Saint-Louis - Paris
- Universitaetsklinikum Koeln - Cologne
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitaetsklinikum Wuerzburg - Würzburg
- Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca - Salamanca
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco
- Stanford University Medical Center - Stanford
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Local Institution - 0008 - Nashville
- Tennessee Oncology - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2030-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06153251
The ClinicalTrials.gov registry entry for NCT06153251 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed and/or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06153251 reports 19 study locations spanning 11 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT06153251 about?
NCT06153251 is a clinical study titled "A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
What is the current status of trial NCT06153251?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 187 participants. The study started on 2024-01-23. Estimated completion is 2030-05-02.
What conditions does trial NCT06153251 study?
This clinical trial studies the following conditions: Relapsed and/or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT06153251?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), BMS-986453 (DRUG).
Who is sponsoring clinical trial NCT06153251?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153251 being conducted?
This trial has 19 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.